Bio News

• Bio News

  Lilly’s Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s Disease

  2024年7月3日 0
• Bio News

  Radionetics Oncology Enters Into Strategic Agreement With Lilly on its proprietary GPCR targeting small molecule radiopharmaceuticals

  2024年7月2日 0
• Bio News

  Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  2024年7月2日 0
• Bio News

  Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

  2024年6月24日 0
• Bio News

  【Breaking News！】Once a Week! Novo Nordisk’s Ultra-Long-Acting Insulin Approved in China for the Treatment of Diabetes

  2024年6月24日 0
• Bio News

  Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

  2024年6月21日 0
• Bio News

  Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

  2024年6月21日 0
• Bio News

  Day One Announces Sale of Priority Review Voucher for $108 Million

  2024年6月20日 0
• Bio News

  Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

  2024年6月20日 0
• Bio News

  Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases

  2024年6月20日 0